Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

European journal of nuclear medicine and molecular imaging - 1 Jun 2016

Li Jiao, Liang Jun, Zhao Teng, Lin Yansong

Abstract excerpt

PURPOSE: As the most frequent and specific genetic alteration in papillary thyroid carcinoma (PTC), BRAF(V600E) has an intimate relationship with more invasive tumour and higher postoperative recurrence risk in PTC patients. We investigate the effect of radioactive iodine (RAI) therapy on the clinical outcome in PTC patients with the BRAF(V600E) mutation without distant metastases. METHODS: This retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Treatment Outcome

Source

Identifiers

PMID: 26780618
DOI: 10.1007/s00259-015-3305-1

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.PMID 26780618Read ↗

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapySemantic proximity Read ↗

Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation.Semantic proximity Read ↗

Response to therapy of papillary thyroid cancer of known BRAF status.Semantic proximity Read ↗

The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.Semantic proximity Read ↗

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerSemantic proximity Read ↗

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?Semantic proximity Read ↗

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinomaSemantic proximity Read ↗

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.Semantic proximity Read ↗

BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.Semantic proximity Read ↗

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.Semantic proximity Read ↗

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.